This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Thoratec Surpasses 10,000 HeartMate II® Implants Worldwide

Stocks in this article: THOR

PLEASANTON, Calif., April 17, 2012 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, today announced that as of April 2012, clinicians have implanted more than 10,000 HeartMate II® Left Ventricular Assist Devices (LVADs) in patients suffering from advanced heart failure (AHF) worldwide. 

The HeartMate II is a small implantable mechanical device that helps circulate blood throughout the body.  Sometimes called a "heart pump" or "VAD," it is designed to supplement the pumping function of the heart for patients whose hearts are too weak to pump blood adequately on their own.

 "Every year, millions of people worldwide develop chronic heart failure, and many will progress to an advanced, debilitating stage of the disease," said Gary Burbach, President and Chief Executive Officer of Thoratec. "Today, we recognize the more than 10,000 individuals who have been implanted with HeartMate II – the device that is setting the standard for proven, long-term support of advanced heart failure patients. I want to congratulate and thank everyone involved for contributing to this milestone event. This is a great achievement for the medical community and, most importantly, for the patients who have benefited from this life-restoring treatment option."

HeartMate II has been extensively studied, both in clinical trials and in commercial, real-world experience, and has been approved by the U.S. Food and Drug Administration (FDA) as well as international regulatory bodies to support advanced heart failure patients.  For individuals with AHF, the heart has difficulty pumping blood and is unable to supply the body with adequate levels of oxygen. As a result, AHF patients feel tired or weak, even when doing simple things, like walking or eating.  The use of an LVAD, such as the HeartMate II, is considered an appropriate treatment option in cases of AHF. Studies have shown that patients treated with an LVAD can live longer and enjoy a much-improved quality of life compared with those being treated with drug therapy alone.[1],[2]

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs